• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

89bio (ETNB)

Common Shares
Sell: $6.50|Buy: $9.50|Change: 0.47 (6.23%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Address




Website

https://www.89bio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
89bio Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
89bio Inc Annual Report for 20252026-02-27T00:00:00
89bio Inc Third Quarter Earnings Results for 20252025-11-07T00:00:00
89bio Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
89bio Inc Annual General Meeting for 20252025-05-29T09:00:00
89bio Inc First Quarter Earnings Results for 20252025-05-09T00:00:00

Previous key dates

NameKey Date
89bio Inc Annual General Meeting for 20252025-05-29T09:00:00
89bio Inc First Quarter Earnings Results for 20252025-05-09T00:00:00
Leerink Partners Global Healthcare Conference2025-03-10T16:20:00
89bio Inc Fourth Quarter Earnings Results for 20242025-02-27T00:00:00
89bio Inc Annual Report for 20242025-02-27T00:00:00
89bio Inc 7th Annual Evercore HealthCONx Conference 20242024-12-03T08:20:00
89bio UBS Global Healthcare Conference 20242024-11-12T00:30:00
89bio Inc Third Quarter Earnings Results for 20242024-11-07T00:00:00
H.C. Wainwright 8th Annual MASH Investor Conference2024-10-07T11:30:00
2024 Cantor Global Healthcare Conference2024-09-17T11:30:00
H.C. Wainwright 26th Annual Global Investment Conference 20242024-09-09T11:30:00
Wells Fargo 2024 Healthcare Conference2024-09-05T12:45:00
89bio Inc Second Quarter Earnings Results for 20242024-08-05T00:00:00
89bio Inc Annual General Meeting for 20242024-05-29T09:00:00
89bio, Inc. KOL Webinar on the Pegozafermin Opportunity 20242024-05-16T10:00:00
BofA Securites 2024 Health Care Conference2024-05-15T14:20:00
89bio Inc First Quarter Earnings Results for 20242024-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.